Acrivon Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Acrivon acquired ACR-525, a Phase 2-ready JAK1 inhibitor identified via its AI platform, targeting eosinophilic esophagitis; also acquired a preclinical PKC-theta program for T-cell disorders. Q3 2026 net loss was $17.9M (vs. $18.2M in Q3 2025); cash position of $77.8M expected to fund operations into Q4 2027. Company announced late-breaking Phase 1/2 data for ACR-2316 (WEE1/PKMYT1 inhibitor) and upcoming ACR-368 interim analysis in Q4 2026.
Why this rating
Strategic pipeline expansion into I&I is meaningful for clinical-stage biotech but ACR-525 is acquired/Phase 2-ready (not transformational). Cash runway remains adequate. Relative to $20.4M market cap, pipeline progress matters moderately but lacks near-term revenue catalysts.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.